AUS
NZ
UK
CA
USA
IND
Headlines:
- Pfizer's Q2 Report and Revenue Expectations
- Historical Stock Performance and Market Trends
- Valuation Insights and Future Predictions
Pfizer (NYSE:PFE) is set to disclose its Q2 2024 financial results on Tuesday, July 30. Analysts anticipate the pharmaceutical giant will report revenues of $12.95 billion and earnings of $0.44 per share on an adjusted basis. These projections fall short of consensus estimates, suggesting a potentially subdued performance for the quarter. Despite expected increases in sales from key products like Eliquis and Prevnar, there are concerns that intensified market competition may lead to revenue that does not meet analyst expectations. Consequently, the current stock price of around $30 appears to reflect these anticipated results.
Over recent years, Pfizer's stock performance has been inconsistent. From early January 2021 to now, PFE shares have dropped by 15%, compared to a 45% gain in the S&P 500 over the same period. The stock experienced significant volatility: a 60% rise in 2021, a 13% decline in 2022, and a sharp 44% decrease in 2023. In contrast, the S&P 500 posted gains of 27% in 2021, a 19% drop in 2022, and a 24% increase in 2023, highlighting Pfizer’s underperformance in the last year.
The broader market has presented challenges for many stocks, including major players in the Healthcare sector like UnitedHealth (UNH) and Johnson & Johnson (JNJ), as well as technology giants such as Google (GOOG), Tesla (NASDAQ:TSLA), and Microsoft (NASDAQ:MSFT). Despite this, the Trefis High Quality (HQ) Portfolio, which includes 30 carefully selected stocks, has outperformed the S&P 500 annually over the same period, offering steadier returns with less risk.
Given the current macroeconomic uncertainties, including high oil prices and elevated interest rates, there are concerns that Pfizer might replicate its 2023 performance and lag behind the S&P 500 over the next 12 months. However, it’s also possible that the company could experience a recovery. From a valuation perspective, Pfizer’s stock seems appropriately priced, with an estimated valuation of $29 per share, aligning closely with its current market value. Currently trading at 13 times the projected earnings of $2.25 per share for 2024, Pfizer’s valuation multiple is lower than the 15 times average observed over the past five years. This decline in valuation is partly due to the strong earnings growth Pfizer experienced during the COVID-19 pandemic, driven by its vaccine and antiviral products.
In the previous quarter, Pfizer reported revenue of $14.9 billion, reflecting a 19% year-over-year decline, primarily due to decreased sales of its COVID-19 products. Excluding these products, sales grew by 11%, buoyed by strong performances from Vyndaqel and Abrysvo. Eliquis and Prevnar also saw positive contributions, with sales increases of 10% and 7%, respectively. However, adjusted net margins fell by over 670 basis points to 31.4%, partly due to rising research and development expenses. Consequently, earnings per share dropped to $0.82, compared to $1.23 in the prior year.
Looking ahead, Pfizer’s Q2 performance is anticipated to benefit from continued growth in Vyndaqel and Abrysvo, alongside increased sales of Prevnar and Eliquis. Sales of COVID-19 products are expected to remain comparable to the previous year. The company forecasts 2024 revenues between $58.5 billion and $61.5 billion, with adjusted earnings ranging from $2.15 to $2.35 per share. Although Pfizer is likely to report year-over-year sales growth, it may still fall short of broader market expectations.
For a deeper understanding of Pfizer’s positioning, it’s beneficial to compare its performance metrics with those of other healthcare stocks. Exploring Peer Comparisons can provide additional insights and valuable industry benchmarks.
